Staar Surgical CO STAA
We take great care to ensure that the data presented and summarized in this overview for STAAR SURGICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAA
View all-
Broadwood Capital Inc New York, NY10.8MShares$447 Million31.17% of portfolio
-
Black Rock Inc. New York, NY7.72MShares$321 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.48MShares$227 Million0.0% of portfolio
-
Baillie Gifford & CO4.11MShares$171 Million0.12% of portfolio
-
State Street Corp Boston, MA1.94MShares$80.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.38MShares$57.3 Million6.17% of portfolio
-
Geode Capital Management, LLC Boston, MA1.1MShares$45.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY942KShares$39.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC867KShares$36 Million0.0% of portfolio
-
Defender Capital, Llc.730KShares$30.3 Million9.92% of portfolio
Latest Institutional Activity in STAA
Top Purchases
Top Sells
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Insider Transactions at STAA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 09
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
May 09
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1
|
$42
$42.56 P/Share
|
May 08
2024
|
Magda Michna Chief Clinical, Regulatory, |
SELL
Payment of exercise price or tax liability
|
Direct |
1,670
-11.89%
|
$68,470
$41.02 P/Share
|
May 08
2024
|
Warren Foust Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,418
-11.89%
|
$99,138
$41.02 P/Share
|
Mar 14
2024
|
Aimee S Weisner |
BUY
Open market or private purchase
|
Direct |
1,750
+13.87%
|
$66,500
$38.11 P/Share
|
Mar 12
2024
|
Wei Jiang |
BUY
Grant, award, or other acquisition
|
Direct |
1,299
+50.0%
|
-
|
Mar 12
2024
|
Arthur C Butcher |
BUY
Grant, award, or other acquisition
|
Direct |
649
+50.0%
|
-
|
Mar 07
2024
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,614
+5.44%
|
-
|
Jan 08
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 08
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,042
+0.04%
|
$109,134
$27.11 P/Share
|
Jan 05
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 05
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
156,734
+0.72%
|
$4,388,552
$28.68 P/Share
|
Jan 04
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 04
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
63,246
+0.59%
|
$1,770,888
$28.91 P/Share
|
Jan 03
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 03
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
6,573
+0.06%
|
$184,044
$28.93 P/Share
|
Jan 03
2024
|
Thomas G Frinzi President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,739
-11.67%
|
$311,431
$29.2 P/Share
|
Dec 29
2023
|
Stephen C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
921
+6.66%
|
$28,551
$31.21 P/Share
|
Dec 29
2023
|
Aimee S Weisner |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+25.99%
|
$99,200
$31.21 P/Share
|
Dec 11
2023
|
Nathaniel Sisitsky General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
21,935
+50.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 34.5K shares |
---|---|
Exercise of conversion of derivative security | 23.1K shares |
Open market or private purchase | 1.99M shares |
Payment of exercise price or tax liability | 19.9K shares |
---|